Michael R. Bishop, MD, hematologic oncologist, professor of medicine and director of the hematopoietic stem cell transplant program at the University of Medicine of Chicago, discusses chimeric antigen receptor (CAR) T cell therapy in non-Hodgkin lymphoma.
According to Bishop, CAR T cells offer another option for patients with mantle cell lymphoma. In addition, CAR T cell therapy in mantle cell lymphoma also has a higher stable remission rate than diffuse large B cell lymphoma. Long-lasting complete remissions without further treatment have been observed. However, questions remain around sustainability and long-term data.
Results are still pending in indolent lymphomas such as follicular lymphoma. However, according to Bishop, the initial results are encouraging. Trial results are expected in late 2021. In terms of multiple myeloma, the duration of responses has not been as high as in lymphomas, but improves over time.
0:08 | It offers an additional option. There are many options for mantle cell lymphoma, but the results from CAR T cells had a higher response rate. And a significant proportion going into stable remission is higher than what we have seen in diffuse large B-cell lymphoma. Long-term data have yet to be determined, and rather in relation to the impact on their natural history, but there are sustained complete remissions without any other therapy and we have just seen how long these will last.
0:46 | And we are awaiting additional results in other forms of non-Hodgkin’s lymphoma, particularly in indolent lymphomas, such as follicular lymphoma, the first results are extremely encouraging. We now have some additional information when you consider Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, we consider these to be initially encouraging results. So we’re going to have these trials available to us, the results of that, in this year. And finally, getting back to multiple myeloma, as I mentioned, we’re going to have our first product approved, which we expect to be commercially available in March of this year, and a number of trials that are very interesting variations of the approaches in terms of targets and double targeting and different receptors. And these results were very exciting in terms of very, very high response rates. I think the disappointing aspect of multiple myeloma, we don’t see the sustained remissions that we see in leukemias and lymphomas, but we do see improvement across protocols over time. So, I think it’s an exciting time for patients to have these various options.